Mark Frigerio

1.7k total citations
22 papers, 1.2k citations indexed

About

Mark Frigerio is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Mark Frigerio has authored 22 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Oncology and 9 papers in Organic Chemistry. Recurrent topics in Mark Frigerio's work include Synthetic Organic Chemistry Methods (6 papers), Cancer Treatment and Pharmacology (5 papers) and DNA Repair Mechanisms (4 papers). Mark Frigerio is often cited by papers focused on Synthetic Organic Chemistry Methods (6 papers), Cancer Treatment and Pharmacology (5 papers) and DNA Repair Mechanisms (4 papers). Mark Frigerio collaborates with scholars based in United Kingdom, United States and Australia. Mark Frigerio's co-authors include Marc Hummersone, Karl J. Hale, Soraya Manaviazar, Andrew F. Kyle, Keith Menear, Xiaoling Cockcroft, Laurent Rigoreau, Xiaobo Sheng, Isa M. Hussaini and Sarah E. Golding and has published in prestigious journals such as Cancer Research, Scientific Reports and Journal of Medicinal Chemistry.

In The Last Decade

Mark Frigerio

22 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Frigerio United Kingdom 15 638 428 382 227 150 22 1.2k
Sylvia Musto United States 18 466 0.7× 328 0.8× 216 0.6× 165 0.7× 92 0.6× 32 943
Philip G. Kasprzyk United States 22 1.1k 1.8× 638 1.5× 299 0.8× 307 1.4× 85 0.6× 50 1.8k
Percy H. Carter United States 23 680 1.1× 444 1.0× 630 1.6× 121 0.5× 146 1.0× 59 1.5k
Suzanne B. Buck United States 8 744 1.2× 648 1.5× 547 1.4× 55 0.2× 232 1.5× 10 1.5k
Nadim Jessani United States 9 909 1.4× 388 0.9× 426 1.1× 126 0.6× 106 0.7× 10 1.3k
Murray J. Towle United States 17 440 0.7× 509 1.2× 211 0.6× 50 0.2× 178 1.2× 24 1.1k
Ashutosh Pal United States 16 525 0.8× 340 0.8× 130 0.3× 203 0.9× 30 0.2× 44 983
Bruce E. Tomczuk United States 20 465 0.7× 396 0.9× 416 1.1× 239 1.1× 43 0.3× 37 1.1k
Mark Humphrey United States 9 835 1.3× 606 1.4× 332 0.9× 97 0.4× 91 0.6× 10 1.5k
Michael F. T. Koehler United States 15 640 1.0× 168 0.4× 231 0.6× 88 0.4× 116 0.8× 21 936

Countries citing papers authored by Mark Frigerio

Since Specialization
Citations

This map shows the geographic impact of Mark Frigerio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Frigerio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Frigerio more than expected).

Fields of papers citing papers by Mark Frigerio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Frigerio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Frigerio. The network helps show where Mark Frigerio may publish in the future.

Co-authorship network of co-authors of Mark Frigerio

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Frigerio. A scholar is included among the top collaborators of Mark Frigerio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Frigerio. Mark Frigerio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Poblocka, Marta, Victoria M. Smith, Ana Sousa Manso, et al.. (2021). Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker. Scientific Reports. 11(1). 20358–20358. 99 indexed citations
2.
Binder, Uli, William McDowell, Rita Tommasi, et al.. (2019). Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4. mAbs. 11(7). 1331–1340. 22 indexed citations
3.
Frigerio, Mark & Andrew F. Kyle. (2018). The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates. Current Topics in Medicinal Chemistry. 17(32). 3393–3424. 32 indexed citations
4.
Zhang, Jihong, Marc Hummersone, Charles S. Matthews, et al.. (2016). Antitumor imidazo[5,1-d]-1,2,3,5-tetrazines: compounds modified at the 3-position overcome resistance in human glioblastoma cell lines. MedChemComm. 7(12). 2332–2343. 16 indexed citations
5.
Iachettini, Sara, Malcolm F. G. Stevens, Mark Frigerio, et al.. (2013). On and off-target effects of telomere uncapping G-quadruplex selective ligands based on pentacyclic acridinium salts. Journal of Experimental & Clinical Cancer Research. 32(1). 68–68. 26 indexed citations
6.
Cano, Céline, Chris Bailey, Julia Bárdos, et al.. (2013). 1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK/PI3-K Inhibitory Activity. Journal of Medicinal Chemistry. 56(16). 6386–6401. 42 indexed citations
7.
Cano, Céline, Olivier Barbeau, C. L. Bailey, et al.. (2010). DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype. Journal of Medicinal Chemistry. 53(24). 8498–8507. 35 indexed citations
8.
Golding, Sarah E., Elizabeth Rosenberg, Nicholas C.K. Valerie, et al.. (2009). Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Molecular Cancer Therapeutics. 8(10). 2894–2902. 285 indexed citations
9.
Albertella, Mark R., Céline Cano, Nicola J. Curtin, et al.. (2008). Identification of potent water-soluble DNA-dependent protein kinase (DNA-PK) inhibitors using a small-molecule library approach [abstract]. Cancer Research. 68. 4156–4156. 3 indexed citations
10.
Murr, Marine Desage‐El, Céline Cano, Bernard T. Golding, et al.. (2008). 8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK). Bioorganic & Medicinal Chemistry Letters. 18(17). 4885–4890. 18 indexed citations
11.
12.
Manaviazar, Soraya, Mark Frigerio, Gurpreet Singh Bhatia, et al.. (2006). Enantioselective Formal Total Synthesis of the Antitumor Macrolide Bryostatin 7. Organic Letters. 8(20). 4477–4480. 66 indexed citations
13.
Hale, Karl J., Mark Frigerio, Soraya Manaviazar, et al.. (2003). Synthesis of a Simplified Bryostatin C-Ring Analogue That Binds to the CRD2 of Human PKC-α and Construction of a Novel BC-Analogue by an Unusual Julia Olefination Process. Organic Letters. 5(4). 499–502. 13 indexed citations
14.
Hale, Karl J., Marc Hummersone, Soraya Manaviazar, & Mark Frigerio. (2002). The chemistry and biology of the bryostatin antitumour macrolides. Natural Product Reports. 19(4). 413–453. 149 indexed citations
15.
Hale, Karl J., Marc Hummersone, Soraya Manaviazar, & Mark Frigerio. (2002). The Chemistry and Biology of the Bryostatin Antitumor Macrolides. ChemInform. 33(45). 244–244. 1 indexed citations
16.
17.
Hale, Karl J., Mark Frigerio, & Soraya Manaviazar. (2001). A Short Synthetic Pathway to a Fully-Functionalized Southern Hemisphere of the Antitumor Macrolide Bryostatin 1. Organic Letters. 3(23). 3791–3794. 16 indexed citations
18.
Hale, Karl J., Marc Hummersone, Jiaqiang Cai, et al.. (2000). Synthetic studies on the A83586C and bryostatin antitumor macrolides and the monamycin antibiotics. Pure and Applied Chemistry. 72(9). 1659–1670. 11 indexed citations
19.
Frigerio, Mark, et al.. (1990). Total synthesis of homochiral 3-deoxy-3-fluoromuscarines.. Gazzetta chimica italiana. 120(4). 275–276. 11 indexed citations
20.
Gandolfi, C., et al.. (1988). Tiamdipines: A new class of Ca++-antagonists. Pharmacological Research Communications. 20. 174–174. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sylvia Musto Breakdown of academic impact, for papers by Philip G. Kasprzyk Breakdown of academic impact, for papers by Percy H. Carter Breakdown of academic impact, for papers by Suzanne B. Buck Breakdown of academic impact, for papers by Nadim Jessani Breakdown of academic impact, for papers by Murray J. Towle Breakdown of academic impact, for papers by Ashutosh Pal Breakdown of academic impact, for papers by Bruce E. Tomczuk Breakdown of academic impact, for papers by Mark Humphrey Breakdown of academic impact, for papers by Michael F. T. Koehler
Rankless by CCL
2026